Projects per year
Personal profile
Biography
Professor Mark Shackleton is Director of Oncology at Alfred Health and Professor of Oncology in the Department of Medicine, Monash Univerisity.
Department of Medicine (Alfred) Research Laboratories - Shackleton Group
After training in medical oncology and at the Ludwig Institute in Melbourne, Prof Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA, with resultant publications in Nature, Cell, Cancer Cell and the New England Journal of Medicine. He was awarded the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and in 2012 received the Australian Science Minister’s Prize for Life Scientist of the Year.
Most recently a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at the Peter MacCallum Cancer Centre, Prof Shackleton’s main clinical interests are centred on patients diagnosed with skin cancer, including melanoma. His research interests include cancer biology, developmental biology, oncogenic signaling pathways and clinical trials.
Research area keywords
- Melanoma
- Cancer Therapeutics
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2017 2023
Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies?
1/02/20 → 31/01/23
Project: Research
Improve access to novel treatments and trials for advanced prostate cancer patients: Precision Oncology Program
Iddawela, M., Risbridger, G. & Shackleton, M.
1/03/19 → 29/02/20
Project: Research
The Hippo Pathway And Melanoma Growth
Harvey, K. F. & Shackleton, M.
National Health & Medical Research Council (NHMRC)
1/01/18 → 31/12/21
Project: Research
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
To, S. Q. G., Azad, A., Shortt, J., Wei, A., Shackleton, M. & Kenealy, M.
1/12/17 → 1/12/20
Project: Research
Translating melanoma discoveries from the laboratory to the clinic
1/08/17 → 23/09/21
Project: Research
Research Output 2003 2019
3
Citations
(Scopus)
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies
Pires da Silva, I., Glitza, I. C., Haydu, L. E., Johnpulle, R., Banks, P. D., Grass, G. D., Goldinger, S. M. A., Smith, J. L., Everett, A. S., Koelblinger, P., Roberts-Thomson, R., Millward, M., Atkinson, V. G., Guminski, A., Kapoor, R., Conry, R. M., Carlino, M. S., Wang, W., Shackleton, M. J., Eroglu, Z. & 5 others, , 1 Jul 2019, In : Pigment Cell and Melanoma Research. 32, p. 553-563 11 p.Research output: Contribution to journal › Article › Research › peer-review
1
Citation
(Scopus)
Personalised surveillance after treatment for high-risk cancer
Guo, C., Lewin, J. & Shackleton, M., 1 Jan 2019, In : Oncotarget. 10, 7, p. 694-695 2 p.Research output: Contribution to journal › Editorial › Other › peer-review
Open Access
7
Citations
(Scopus)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., Hatzimihalis, A., Henderson, M. A., Shackleton, M., Haydon, A., Mar, V., Gyorki, D. E., Oudit, D., Dawson, M. A., Hicks, R. J., Lorigan, P. & 4 others, , 1 May 2019, In : Annals of Oncology. 30, 5, p. 804-814 11 p.Research output: Contribution to journal › Article › Research › peer-review
Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma
Zhang, X., Tang, J. Z., Vergara, I. A., Zhang, Y., Szeto, P., Yang, L., Mintoff, C., Colebatch, A., McIntosh, L., Mitchell, K. A., Shaw, E., Rizos, H., Long, G. V., Hayward, N., McArthur, G. A., Papenfuss, A. T., Harvey, K. F. & Shackleton, M., 1 Jul 2019, In : Molecular Cancer Research. 17, 7, p. 1435-1449 15 p.Research output: Contribution to journal › Article › Research › peer-review
12
Citations
(Scopus)
Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
Mitchell, E. L., Lau, P. K. H., Khoo, C., Liew, D., Leung, J., Liu, B., Rischin, A., Frauman, A. G., Kee, D., Smith, K., Brady, B., Rischin, D., Gibson, A., Mileshkin, L., Klein, O., Weickhardt, A., Arulananda, S., Shackleton, M., McArthur, G., Östör, A. & 7 others, , 1 Dec 2018, In : European Journal of Cancer. 105, p. 88-102 15 p.Research output: Contribution to journal › Article › Research › peer-review